Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Expands By 65.3%

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 39,500 shares, an increase of 65.3% from the October 15th total of 23,900 shares. Based on an average daily trading volume, of 58,100 shares, the short-interest ratio is currently 0.7 days. Approximately 9.1% of the company’s shares are short sold.

Cadrenal Therapeutics Trading Up 0.1 %

Cadrenal Therapeutics stock traded up $0.01 during midday trading on Thursday, hitting $16.57. 63,551 shares of the company were exchanged, compared to its average volume of 30,027. The stock has a fifty day simple moving average of $13.45. The company has a market cap of $17.73 million, a P/E ratio of -2.48 and a beta of 1.52. Cadrenal Therapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $32.55.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lifted their price objective on Cadrenal Therapeutics from $3.00 to $32.00 and gave the company a “buy” rating in a research note on Monday.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.